Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Massachusetts General Hospital · Harvard University · +20 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
845
total citations
- FWCI
- 33.16
- Percentile
- 100%
- References
- 34
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Ramucirumab
- Medicine
- Sorafenib
- Internal medicine
- Placebo
- Hepatocellular carcinoma
- Population
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.